TriSalus Life Sciences (TLSI) Expected to Release Quarterly Earnings on Thursday

TriSalus Life Sciences (NASDAQ:TLSI) is expected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.1550) per share and revenue of $10.2670 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

TriSalus Life Sciences Trading Down 0.2%

Shares of NASDAQ TLSI opened at $4.74 on Wednesday. The company has a market cap of $291.13 million, a PE ratio of -3.36 and a beta of 0.43. The company has a debt-to-equity ratio of 2.58, a quick ratio of 5.46 and a current ratio of 5.78. The firm’s 50 day moving average price is $4.06 and its 200-day moving average price is $4.31. TriSalus Life Sciences has a 52-week low of $2.20 and a 52-week high of $7.95.

Insider Activity

In related news, CEO Mary T. Szela bought 39,682 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was purchased at an average price of $2.59 per share, for a total transaction of $102,776.38. Following the acquisition, the chief executive officer owned 1,065,215 shares in the company, valued at $2,758,906.85. This trade represents a 3.87% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Mats Wahlstrom acquired 60,000 shares of the business’s stock in a transaction on Friday, May 15th. The shares were purchased at an average price of $2.53 per share, for a total transaction of $151,800.00. Following the transaction, the director directly owned 147,555 shares of the company’s stock, valued at approximately $373,314.15. The trade was a 68.53% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 719,682 shares of company stock valued at $1,804,176 in the last ninety days. Insiders own 16.30% of the company’s stock.

Institutional Trading of TriSalus Life Sciences

Several institutional investors and hedge funds have recently made changes to their positions in TLSI. Invesco Ltd. bought a new stake in TriSalus Life Sciences during the 4th quarter valued at about $72,000. Man Group plc bought a new stake in shares of TriSalus Life Sciences in the 4th quarter valued at about $102,000. Abel Hall LLC purchased a new position in TriSalus Life Sciences in the fourth quarter worth $73,000. Kotler Kevin purchased a new position in TriSalus Life Sciences during the 4th quarter worth $1,013,000. Finally, Price T Rowe Associates Inc. MD acquired a new position in shares of TriSalus Life Sciences during the fourth quarter valued at about $104,000. 2.58% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently commented on TLSI. Lake Street Capital reduced their price objective on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Weiss Ratings lowered TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, TriSalus Life Sciences has a consensus rating of “Hold” and a consensus target price of $7.50.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.